Chronic hepatitis B and hepatocarcinogenesis: does prevention of "collateral damage" bring the cure?

Abstract

HepatologyVolume 37, Issue 3 p. 707-710 ElsewhereFree Access Chronic hepatitis B and hepatocarcinogenesis: Does prevention of “collateral damage” bring the cure? Tobias Manigold M.D., Tobias Manigold M.D. Liver Diseases Section, NIDDK, National Institutes of Health, DHHS Bethesda, MDSearch for more papers by this authorBarbara Rehermann M.D., Barbara Rehermann M.D. Liver Diseases Section, NIDDK, National Institutes of Health, DHHS Bethesda, MDSearch for more papers by this author Tobias Manigold M.D., Tobias Manigold M.D. Liver Diseases Section, NIDDK, National Institutes of Health, DHHS Bethesda, MDSearch for more papers by this authorBarbara Rehermann M.D., Barbara Rehermann M.D. Liver Diseases Section, NIDDK, National Institutes of Health, DHHS Bethesda, MDSearch for more papers by this author First published: 30 December 2003 https://doi.org/10.1002/hep.510370328Citations: 9AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Resnick RH, Koff R. Hepatitis C-related hepatocellular carcinoma. Prevalence and significance. Arch Intern Med 1993; 153: 1672– 1677. 2 Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19: 65– 91. 3 Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998; 188: 341– 350. 4 Desbarats J, Newell MK. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med 2000; 6: 920– 923. 5 Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells—a mechanism of immune evasion? Nat Med 1996; 2: 1361– 1366. 6 Nakamoto Y, Kaneko S, Fan H, Momoi T, Tsutsui H, Nakanishi K, Kobayashi K, et al. Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy. J Exp Med 2002; 196: 1105– 1111. 7 Ando K, Moriyama T, Guidotti LG, Wirth S, Schreiber RD, Schlicht HJ, Huang SN, et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 1993; 178: 1541– 1554. 8 Kakimi K, Lane TE, Wieland S, Asensio VC, Campbell IL, Chisari FV, Guidotti LG. Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med 2001; 194: 1755– 1766. 9 Miwa K, Asano M, Horai R, Iwakura Y, Nagata S, Suda T. Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 1998; 4: 1287– 1292. 10 Tsutsui H, Kayagaki N, Kuida K, Nakano H, Hayashi N, Takeda K, Matsui K, et al. Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity 1999; 11: 359– 367. 11 Sitia G, Isogawa M, Kakimi K, Wieland SF, Chisari FV, Guidotti LG. Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 2002; 99: 13717– 13722. 12 Guidotti LG, Matzke B, Schaller H, Chisari FV. High-level hepatitis B virus replication in transgenic mice. J Virol 1995; 69: 6158– 6169. 13 Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825– 829. 14 Shimoyama T, Sawada K, Hiwatashi N, Sawada T, Matsueda K, Munakata A, Asakura H, et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apheresis 2001; 16: 1– 9. 15 Nakamoto Y, Guidotti L, Pasquetto V, Schreiber RD, Chisari FV. Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice. J Immunol 1997; 158: 5692– 5697. 16 Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12: 121– 127. Citing Literature Volume37, Issue3March 2003Pages 707-710 ReferencesRelatedInformation